Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not
Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a multibillion-dollar write-down actually signal about income reliability.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Pfizer (NYSE:PFE | PFE Price Prediction) yields 6.24%. Johnson & Johnson (NYSE:JNJ) yields 2.07%. The yield gap reflects how investors price each payout as patents expire. The bigger number needs examination before calling it the better bet.
Pfizer’s Bigger Yield Comes With a Frozen Payout
Pfizer has paid $0.43 a quarter since 2025, up from $0.38 in 2020. Adjusted EPS guidance of $2.80 to $3.00 puts the $1.72 annual payout at about 57% to 61% of earnings. Free cash flow yield of 5.79% falls below the dividend yield, meaning free cash flow doesn’t fully fund the payout. Leverage ended the second quarter at 2.7 times, with management expecting it to hold steady or rise.
On the August 4 call, Pfizer’s chief executive said: “Even in the most stretched scenarios that we are running, we will be able to maintain our dividend.” He promised to keep the payout flat, with raises resuming only after the period when key drugs lose patent protection.
Johnson & Johnson raised its quarterly dividend 3.1% to $1.34 in April, its 64th consecutive annual increase. Free cash flow outlook of nearly $21 billion easily covers a dividend bill of about $12.9 billion.
| Dividend Lens | Pfizer | Johnson & Johnson |
|---|---|---|
| Forward Annual Dividend | $1.72 | $5.36 |
| Payout vs. Adjusted EPS Guidance | ~57% to ~61% | ~47% |
| Recent Trend | Flat | Raised |
Patent Cliffs Expose Pfizer’s Thinner Bench
Pfizer expects a $1.5 billion hit from generics and biosimilars this year and doesn’t project growth until 2029. Padcev grew 39% in the first quarter. A lung cancer trial that missed its survival goal forced a $4.3 billion write-down, driving Pfizer to a second-quarter loss of 4 cents per share.
Johnson & Johnson is absorbing its biggest patent loss. Stelara sales fell 55.7%, yet the rest of the business grew double digits. Tremfya sales rose 71%. The CFO cited 28 products and platforms each generating more than $1 billion annually.
A Prostate Cancer Readout and a December Review Come Next
Watch for Pfizer’s prostate cancer drug mefrometastat data in the fourth quarter and Johnson & Johnson’s business review on December 8.
Why I Trust Johnson & Johnson’s Dividend More
Johnson & Johnson’s dividend looks better protected. Pfizer’s higher yield compensates for a flat dividend, rising debt, and a pipeline that took a multibillion-dollar write-down. Johnson & Johnson covers its dividend with room to spare, and Stelara’s decline is already absorbed. The stock rose 41.25% over the past year versus 13.72% for Pfizer. For income-focused investors, the lower yield comes with the longer track record of raises.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
